Swedish Orphan Biovitrum AB (publ)

OM:SOBI BTA Stock Report

Market Cap: SEK 74.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Swedish Orphan Biovitrum Management

Management criteria checks 3/4

Swedish Orphan Biovitrum's CEO is Guido Oelkers, appointed in May 2017, has a tenure of 6.33 years. total yearly compensation is SEK47.27M, comprised of 24.2% salary and 75.8% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth SEK81.66M. The average tenure of the management team and the board of directors is 4.7 years and 3.5 years respectively.

Key information

Guido Oelkers

Chief executive officer

SEK 47.3m

Total compensation

CEO salary percentage24.2%
CEO tenure6.3yrs
CEO ownership0.1%
Management average tenure4.7yrs
Board average tenure3.5yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Guido Oelkers's remuneration changed compared to Swedish Orphan Biovitrum's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

SEK 3b

Mar 31 2023n/an/a

SEK 3b

Dec 31 2022SEK 47mSEK 11m

SEK 3b

Sep 30 2022n/an/a

SEK 2b

Jun 30 2022n/an/a

SEK 3b

Mar 31 2022n/an/a

SEK 3b

Dec 31 2021SEK 42mSEK 10m

SEK 3b

Sep 30 2021n/an/a

SEK 3b

Jun 30 2021n/an/a

SEK 3b

Mar 31 2021n/an/a

SEK 3b

Dec 31 2020SEK 33mSEK 10m

SEK 3b

Sep 30 2020n/an/a

SEK 3b

Jun 30 2020n/an/a

SEK 3b

Mar 31 2020n/an/a

SEK 4b

Dec 31 2019SEK 33mSEK 10m

SEK 3b

Sep 30 2019n/an/a

SEK 3b

Jun 30 2019n/an/a

SEK 3b

Mar 31 2019n/an/a

SEK 3b

Dec 31 2018SEK 26mSEK 9m

SEK 2b

Sep 30 2018n/an/a

SEK 2b

Jun 30 2018n/an/a

SEK 2b

Mar 31 2018n/an/a

SEK 1b

Dec 31 2017SEK 16mSEK 5m

SEK 1b

Compensation vs Market: Guido's total compensation ($USD4.27M) is above average for companies of similar size in the Swedish market ($USD2.36M).

Compensation vs Earnings: Guido's compensation has been consistent with company performance over the past year.

CEO

Guido Oelkers (58 yo)

6.3yrs

Tenure

SEK 47,270,000

Compensation

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Leadership Team

NamePositionTenureCompensationOwnership
Guido Oelkers
CEO & President6.3yrsSEK 47.27m0.11%
SEK 81.7m
Henrik Stenqvist
Chief Financial Officer5.2yrsno data0.015%
SEK 10.8m
Torbjörn Hallberg
General Counsel & Head of Legal Affairs4.7yrsno data0.0079%
SEK 5.8m
Daniel Rankin
Head of Strategy & Corporate Development1.7yrsno data0.0058%
SEK 4.3m
Pablo de Mora
Head of Global Marketing & Access1.7yrsno data0.0017%
SEK 1.3m
Lena Bjurner
Head of Human Resourcesless than a yearno datano data
Armin Reininger
Senior Scientific & Medical Advisor6.7yrsno data0.0047%
SEK 3.5m
Norbert Oppitz
Head of International5.9yrsno data0.010%
SEK 7.6m
Sofiane Fahmy
Head of Europe4.7yrsno data0.0078%
SEK 5.8m
Duane Barnes
Head of North America2.7yrsno datano data
Mahmood Ladha
Head of Strategic Transformation Operationsno datano data0.0019%
SEK 1.4m
Christine Wesstrom
Head of Technical Operations1.5yrsno data0.0031%
SEK 2.3m

4.7yrs

Average Tenure

55.5yo

Average Age

Experienced Management: SOBI BTA's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hans Wigzell
Chairman of Scientific Advisory Board22.7yrsSEK 158.00kno data
Helena Saxon
Director12.4yrsSEK 788.00k0.0059%
SEK 4.4m
Bo Hansen
Independent Chairman1.3yrsSEK 667.00k0.021%
SEK 15.8m
Anders Ullman
Directorless than a yearSEK 420.00k0.00088%
SEK 653.5k
Stephen O'Rahilly
Member of Scientific Advisory Boardno datano datano data
Ralf Pettersson
Member of Scientific Advisory Boardno datano datano data
Stefan Del Prato
Member of Scientific Advisory Boardno datano datano data
Jonathan Sanders Arch
Member of Scientific Advisory Boardno datano datano data
Annette Clancy
Independent Director9.3yrsSEK 648.00k0.0010%
SEK 750.1k
Staffan Schuberg
Independent Director3.3yrsSEK 677.00k0.0019%
SEK 1.4m
Katy Mazibuko
Employee Representative Directorless than a yearno datano data
Erika Husing
Employee Representative Director3.7yrsno data0.000020%
SEK 14.9k

3.5yrs

Average Tenure

59.5yo

Average Age

Experienced Board: SOBI BTA's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/27 23:56
End of Day Share Price 2023/09/26 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander LindströmABG Sundal Collier
Rosie TurnerBarclays
Brian BalchinBarclays